Abbisko Therapeutics Co, Ltd   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2016)

Organization Overview

First Clinical Trial
2019
NCT04192344
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Abbisko Therapeutics Co, Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

Pimicotinib (4 trials)

Drugs in Phase 2 Trials (5)

absk-011 (2 trials)

azd4547 (2 trials)

Mavorixafor (1 trial)

tislelizumab (1 trial)

tocilizumab (actemra) (1 trial)

Drugs in Phase 1 Trials (7)

absk043 (1 trial)

absk061 (1 trial)

absk091 (1 trial)

absk121 (1 trial)

absk201 (1 trial)

itraconazole (sporanox) (1 trial)

rifampin (1 trial)

Indications

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 13